Singapore markets closed
Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,887.29 -741.24 (-1.15%) CMC Crypto 200
1,329.81 -66.72 (-4.78%)
GILD Jun 2024 82.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 01:43PM EDT. Market open.
| Previous close | 0.0400 |
| Open | 0.0700 |
| Bid | 0.0000 |
| Ask | 0.0700 |
| Strike | 82.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0700 - 0.0700 |
| Contract range | N/A |
| Volume | |
| Open interest | 968 |
ZacksGilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
- Thomson Reuters StreetEvents
Q1 2024 Gilead Sciences Inc Earnings Call
Q1 2024 Gilead Sciences Inc Earnings Call
Business WireFDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of
© 2024 Yahoo. All rights reserved.